Next week, the biopharma world will see eagerly awaited results from a trial that could shape care for patients with an increasingly common heart condition — and determine which companies stand to reap billions.
The trial of vutrisiran, from Alnylam Pharmaceuticals, was already announced as positive, with the drug successfully cutting the risk of death and cardiovascular complications in patients with the disease, called transthyretin amyloid cardiomyopathy, or ATTR-CM. Given the strong data, the RNA-interference therapy is expected to win regulatory approval.
But Alnylam’s drug is not the only option for patients. Pfizer has a pair of competing therapies, and BridgeBio has one nearing approval. Investors and cardiologists have been anticipating the full results of Alnylam’s HELIOS-B trial, which are scheduled to be presented next Friday, Aug. 30, in London at the annual meeting of the European Society of Cardiology.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
